← All trials
NCT04852705
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 31, 2021
- Primary completion
- Nov 30, 2021
- Completion date
- Nov 30, 2022
- First posted
- Apr 21, 2021
- Last posted
- Apr 22, 2021
- Enrollment
- 28000
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Shenzhen Kangtai Biological Products Co., LTDLead sponsor
- Beijing Minhai Biotechnology Co., LtdCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.